335 related articles for article (PubMed ID: 10221266)
1. Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ; Nash A
Prostate; 1999 Apr; 39(1):47-53. PubMed ID: 10221266
[TBL] [Abstract][Full Text] [Related]
2. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
Kolvenbag GJ; Blackledge GR; Gotting-Smith K
Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389
[TBL] [Abstract][Full Text] [Related]
3. Worldwide activity and safety of bicalutamide: a summary review.
Kolvenbag GJ; Blackledge GR
Urology; 1996 Jan; 47(1A Suppl):70-9; discussion 80-4. PubMed ID: 8560681
[TBL] [Abstract][Full Text] [Related]
4. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
5. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
7. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
8. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
9. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.
Blackledge GR; Cockshott ID; Furr BJ
Eur Urol; 1997; 31 Suppl 2():30-9. PubMed ID: 9074908
[TBL] [Abstract][Full Text] [Related]
10. Clinical progress with a new antiandrogen, Casodex (bicalutamide).
Blackledge GR
Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470
[TBL] [Abstract][Full Text] [Related]
11. Bicalutamide in advanced prostate cancer. A review.
Goa KL; Spencer CM
Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
[TBL] [Abstract][Full Text] [Related]
12. High-dose bicalutamide monotherapy for the treatment of prostate cancer.
Blackledge GR
Urology; 1996 Jan; 47(1A Suppl):44-7; discussion 48-53. PubMed ID: 8560678
[TBL] [Abstract][Full Text] [Related]
13. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
14. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.
Smith MR; Fallon MA; Goode MJ
Urology; 2003 Jan; 61(1):127-31. PubMed ID: 12559282
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Kolvenbag GJ; Iversen P; Newling DW
Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
[TBL] [Abstract][Full Text] [Related]
18. Combined androgen blockade: the case for bicalutamide.
Klotz L; Schellhammer P
Clin Prostate Cancer; 2005 Mar; 3(4):215-9. PubMed ID: 15882477
[TBL] [Abstract][Full Text] [Related]
19. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
20. Combined androgen blockade in advanced prostate cancer: looking back to move forward.
Chodak G; Gomella L; Phung de H
Clin Genitourin Cancer; 2007 Sep; 5(6):371-8. PubMed ID: 17956709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]